Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities.

Vashchenko N, Abrahamsson PA.

Eur Urol. 2005 Feb;47(2):147-55. Review.

PMID:
15661408
2.

Serum interleukin-8 is elevated in men with prostate cancer and bone metastases.

Lehrer S, Diamond EJ, Mamkine B, Stone NN, Stock RG.

Technol Cancer Res Treat. 2004 Oct;3(5):411.

PMID:
15453805
3.

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.

Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, Kung HJ.

Oncogene. 2004 Mar 18;23(12):2197-205.

PMID:
14767470
4.

Epidemiology of inflammation and prostate cancer.

Platz EA, De Marzo AM.

J Urol. 2004 Feb;171(2 Pt 2):S36-40. Review.

PMID:
14713751
5.

Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.

Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G, Chang C.

Cancer Res. 2002 Nov 1;62(21):6039-44.

6.

Chemokines, chemokine receptors and small-molecule antagonists: recent developments.

Onuffer JJ, Horuk R.

Trends Pharmacol Sci. 2002 Oct;23(10):459-67. Review.

PMID:
12368070
7.

Androgen receptor as a target in androgen-independent prostate cancer.

Balk SP.

Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9. Review.

PMID:
12231070
9.

Chemokine receptors.

Horuk R.

Cytokine Growth Factor Rev. 2001 Dec;12(4):313-35. Review.

PMID:
11544102
10.

Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM.

Cancer Res. 2001 Apr 1;61(7):2892-8.

11.

CL1-GFP: an androgen independent metastatic tumor model for prostate cancer.

Patel BJ, Pantuck AJ, Zisman A, Tsui KH, Paik SH, Caliliw R, Sheriff S, Wu L, deKernion JB, Tso CL, Belldegrun AS.

J Urol. 2000 Oct;164(4):1420-5.

PMID:
10992426
12.

Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma.

Grobholz R, Bohrer MH, Siegsmund M, J√ľnemann KP, Bleyl U, Woenckhaus M.

Pathol Res Pract. 2000;196(5):277-84.

PMID:
10834383
13.

Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.

Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP.

Clin Cancer Res. 2000 May;6(5):2104-19.

14.

Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells.

Yeh S, Kang HY, Miyamoto H, Nishimura K, Chang HC, Ting HJ, Rahman M, Lin HK, Fujimoto N, Hu YC, Mizokami A, Huang KE, Chang C.

Endocrine. 1999 Oct;11(2):195-202.

PMID:
10709768
15.

Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment.

Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA.

Prostate. 2000 Mar 1;42(4):274-9.

PMID:
10679756
16.

CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor.

Reiland J, Furcht LT, McCarthy JB.

Prostate. 1999 Oct 1;41(2):78-88.

PMID:
10477904
17.

Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells.

Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, Glass M, Wilke C, Xue YY, Sitterding S, Kunkel SL, Burdick MD, Strieter RM.

Am J Pathol. 1999 May;154(5):1503-12.

18.

Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate.

Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang C.

J Biol Chem. 1999 Mar 19;274(12):8316-21.

19.

Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer.

Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GL Jr, Vessella RL, Ralph D.

Urology. 1999 Jan;53(1):139-47.

PMID:
9886603
20.

Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.

Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z.

Cancer Res. 1998 Oct 15;58(20):4640-5.

Supplemental Content

Support Center